Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Blood. 2013 Nov 28;122(23):3843-4. doi: 10.1182/blood-2013-10-531103.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Antiviral Agents / administration & dosage
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Infection Control / methods
  • Janus Kinases / antagonists & inhibitors
  • Nitriles
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / immunology
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrazoles / adverse effects*
  • Pyrimidines
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • Antiviral Agents
  • Immunosuppressive Agents
  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinases